Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:activities |
antagonist of neurotensin receptor
|
| gptkbp:affects |
under investigation
|
| gptkbp:analyzes |
investigational new drug
|
| gptkbp:class |
gptkb:drug
|
| gptkbp:clinical_trial |
gptkb:United_States
Phase 2 moderate bioavailability narrow therapeutic window measures of efficacy and safety sponsored by Allergan |
| gptkbp:collaborations |
various research institutions
with academic institutions with pharmaceutical companies |
| gptkbp:combatants |
high affinity for NT S1 receptor
|
| gptkbp:composed_of |
multi-step synthesis
|
| gptkbp:developed_by |
gptkb:Allergan
|
| gptkbp:dissolved |
soluble in DMSO
slightly soluble in water |
| gptkbp:dosage_form |
once daily
|
| gptkbp:feedback |
generally positive
|
| https://www.w3.org/2000/01/rdf-schema#label |
ALX-0726
|
| gptkbp:ingredients |
C20 H24 N2 O2 S
|
| gptkbp:interacts_with |
potential interactions with other medications
|
| gptkbp:invention |
patented
U S123456789 |
| gptkbp:investment |
high potential in treatment market
|
| gptkbp:is_effective_against |
promising results in trials
|
| gptkbp:is_tested_for |
clinical trials
|
| gptkbp:is_used_for |
treatment of schizophrenia
|
| gptkbp:manager |
oral
|
| gptkbp:market |
pending
|
| gptkbp:number_of_stages |
completed Phase 1
ongoing Phase 2 |
| gptkbp:population |
adults with schizophrenia
|
| gptkbp:project |
in development
|
| gptkbp:publishes |
published in medical journals
|
| gptkbp:receives_funding_from |
funded by NIH
|
| gptkbp:regulatory_compliance |
not yet approved
|
| gptkbp:research |
results published in peer-reviewed journals
conducted in animal models |
| gptkbp:research_areas |
mental health
psychiatry |
| gptkbp:research_focus |
neuropsychiatric disorders
|
| gptkbp:safety_features |
under evaluation
ongoing safety monitoring |
| gptkbp:scientific_goals |
improve treatment options for schizophrenia
|
| gptkbp:side_effect |
dizziness
fatigue nausea monitoring required |
| gptkbp:social_structure |
contains a sulfonamide group
|
| gptkbp:student_enrollment |
ongoing patient enrollment
|
| gptkbp:targets |
gptkb:neurotensin_receptor_1
schizophrenia |
| gptkbp:weight |
348.48 g/mol
|
| gptkbp:year_created |
gptkb:2015
|
| gptkbp:bfsParent |
gptkb:Ablynx
|
| gptkbp:bfsLayer |
4
|